Regulatory matrix

91 published regulatory records. Each cites an official source and the date it was checked. A regulatory status says what one regulator recorded for one scope. It is not evidence of efficacy or safety, and one jurisdiction’s action does not apply in another. Pairs marked “No published record” mean only that WPF has published nothing for that jurisdiction. They do not mean no regulatory action exists or that a review is scheduled. Product or formulation is shown as “Not recorded” because the record does not capture it. The action label comes from the linked official source, not from the jurisdiction name.

Download filtered CSV

8 rows

Regulatory records by peptide and jurisdiction
PeptideJurisdictionRegulatorProduct or formulationScopeActionLinked sourceDate checked
ElamipretideEuropean UnionEMANot recordedEMA orphan designation is not marketing authorization; no EU marketing authorization was identified in the reviewed official record.No approval recordedEMA orphan designation EU/3/21/2430Linked source: www.ema.europa.eu2026-09-09
ElamipretideUnited StatesFDANot recordedImprove muscle strength in adults and pediatric patients with Barth syndrome weighing at least 30 kg.Approval recordedFDA accelerated approval announcementLinked source: www.fda.gov2026-09-09
ElamipretideUnited KingdomMHRANot recordedNot recordedNo published record——
ElamipretideCanadaHealth CanadaNot recordedNot recordedNo published record——
ElamipretideAustraliaTGANot recordedNot recordedNo published record——
ElamipretideJapanPMDA / MHLWNot recordedNot recordedNo published record——
ElamipretideChinaNMPANot recordedNot recordedNo published record——
ElamipretideSport (WADA)WADANot recordedNot recordedNo published record——